Press Releases

Submission supported by data from Phase 3 pivotal AFFIRM study If approved, adult Crohn's disease patients will have an additional option for induction of risankizumab-rzaa which is already approved for intravenous (IV) inductionNORTH CHICAGO, Ill., April 27, 2026 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced that it has submitted an application to the U.S. Food and Drug Administration (FDA) seeking approval for SKYRIZI® (risankizumab-rzaa) for subcutaneous (SC) induction for the treatment of adult patients with moderately to severely active Crohn's disease (CD). "Crohn's disease is a chronic inflammatory condition that affects an estimated 1 million Americans, and its impact often reac

Traeger, Inc. ("Traeger" or the "Company") (NYSE:COOK), creator and category leader of the wood pellet grill, today announced that it will release its first quarter 2026 financial results after market close on Monday, May 11, 2026. Management will host a conference call at 4:30 p.m. Eastern Time to discuss its financial results. Those who wish to participate in the call may do so by dialing (833) 461-5787 or +1 (585) 542-9983 for international callers, conference ID 832752707. To pre-register for the conference call, please visit Traeger First Quarter 2026 Earnings Conference Call. The conference call will also be webcast live at https://investors.traeger.com. For those unable to partic

Real-world data presented at HRS 2026 add to the body of evidence supporting a shift away from short-duration Holter monitoring toward up to 14 days of continuous, uninterrupted monitoring with Zio® ambulatory ECG devices to reduce missed arrhythmias and provide a more complete assessment of arrhythmia burden, including in post-ablation and pregnancy populations.1-2Findings raise important considerations for post-ablation anticoagulation decisions based on prior studies such as the OCEAN trial that relied on short-duration (24–48-hour) monitoring, as these data show this approach would miss AF recurrence in 26% of patients.1 SAN FRANCISCO, April 27, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdin

FOSTER CITY, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage oncology company, today announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to TERN-701, a novel, oral allosteric BCR::ABL1 inhibitor, for the treatment of adult patients with Ph+ CML in the chronic phase without the T315I mutation previously treated with two or more TKIs. "There remains an urgent need for CML treatments that offer improved efficacy, safety, and tolerability over current therapies," said Scott Harris, chief development and operations officer at Terns. "This designation from the FDA su

Priority Review is granted to medicines that may offer significant improvements in safety or effectiveness for serious conditions like warm autoimmune hemolytic anemia, a life-threatening disease in which pathogenic immunoglobulin G autoantibodies attach to and destroy red blood cells, leading to debilitating anemiaIMAAVY is designed to target the underlying cause of warm autoimmune hemolytic anemia by reducing circulating immunoglobulin G, including autoantibodies, while preserving critical immune functions Pivotal study showed rapid and durable hemoglobin responsea and fatigue improvementb compared to placebo in patients with warm autoimmune hemolytic anemiaSPRING HOUSE, Pa., April 27, 202

BOSTON, April 27, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), a clinical stage company pioneering RNA and immuno-oncology therapeutics for the treatment of high risk and advanced cancers, today announced the appointment of Anna Moore, PhD, as Chair of its Scientific Advisory Board and the signing of a sponsored research agreement (SRA) with Michigan State University (MSU). Dr. Moore, Associate Dean for Research Development, Director of the Precision Health Program and Professor in the Departments of Radiology and Physiology at Michigan State University, is a

BATON ROUGE, La. , April 27, 2026 (GLOBE NEWSWIRE) -- Business First Bancshares, Inc. (NASDAQ:BFST) (Business First), parent company of b1BANK, today announced its unaudited results for the quarter ended March 31, 2026. Business First reported net income available to common shareholders of $22.2 million or $0.68 per diluted common share, an increase of $1.2 million and a decrease of $0.03, respectively, compared to the linked quarter. On a non-GAAP basis, core net income for the quarter ended March 31, 2026, which excludes certain income and expenses, was $24.0 million or $0.73 per diluted common share, an increase of $0.5 million and a decrease of $0.06 from the linked quarter. The quarte

PWM Wealth Tech Awards recognize RBC's strategy of pairing top-tier advisors with intelligent technology to drive growth and client outcomesTORONTO, April 27, 2026 /CNW/ - RBC Wealth Management, Canada's largest full-service wealth management firm, has won two prestigious awards at the PWM Wealth Tech Awards, securing Best Private Bank for Digitally Empowering Relationship Managers in Canada and Best Private Bank for Use of Technology in Canada, for its capabilities across RBC's Canadian wealth management and private banking businesses. These awards recognize RBC's leadership in

HALLANDALE BEACH, Fla., April 27, 2026 /PRNewswire/ -- NextPlat Corp (NASDAQ:NXPL, NXPLW), NXPLW) ("NextPlat" or the "Company"), a global consumer products and services company providing healthcare and technology solutions through e-commerce and retail channels worldwide, today announced that on April 27, 2026, the Company received a letter (the "Compliance Letter") from The Nasdaq Stock Market LLC ("Nasdaq") informing the Company that it has regained compliance with the minimum bid price requirement of $1.00 per share under Nasdaq Listing Rule 5550(a)(2). As a result, the matter has been closed.

CLEVELAND, April 27, 2026 /PRNewswire/ -- Avient Corporation (NYSE:AVNT), an innovator of materials solutions, announced today that Giuseppe (Joe) Di Salvo has been promoted and named Senior Vice President and Chief Financial Officer, effective June 1, 2026. He will succeed Jamie A. Beggs, who will be leaving Avient June 1, 2026 to pursue other opportunities. Mr. Di Salvo brings 25 years of financial experience, including nearly 15 years at Avient, with extensive experience in investor relations, accounting, financial planning and analysis, and treasury. This diverse experience

Sierra Bancorp (NASDAQ:BSRR), parent of Bank of the Sierra, today announced its unaudited financial results for the quarter ended March 31, 2026. Sierra Bancorp reported consolidated net income of $12.5 million, or $0.96 per diluted share, for the first quarter of 2026 compared to $9.1 million, or $0.65 per diluted share, in the first quarter of 2025. Highlights for the First Quarter of 2026 (unless otherwise stated): Strong Quarterly Earnings Metrics Diluted earnings per share increased $0.31, or 47%, from the same quarter in 2025. Return on average assets improved to 1.39% compared to 1.02% for the same quarter in 2025. Return on average equity rose to 13.88% compared to 10.4

WALTHAM, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced an abstract accepted for poster presentation, sharing data on the long-term impact of XPHOZAH® (tenapanor) on serum electrolytes and select nutrition biomarkers, at the National Kidney Foundation's (NKF) Spring Clinical Meetings, to be held May 7-10, 2026, in New Orleans. XPHOZAH, the first and only phosphate absorption inhibitor (PAI), is approved by the U.S. Food and Drug Administration to reduce serum phosphorus in adults with chroni

SAN CARLOS, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will host a conference call and live audio webcast on Thursday, May 7, 2026 at 8:30 a.m. ET to report its first quarter 2026 financial results and corporate updates. To listen to the live or archived audio webcast, please register at https://edge.media-server.com/mmc/p/wmx3s4fc. The live and archived webcast can be accessed in the Investors section of the Company's website, IR.Iovance.com. The archived webcast will be available fo

AVENTURA, Fla., April 27, 2026 (GLOBE NEWSWIRE) -- Safe Pro Group Inc. (NASDAQ:SPAI) ("Safe Pro" or the "Company"), a developer of artificial intelligence (AI)-enabled defense, security, and situational awareness solutions, will demonstrate its NODE-X AI edge platform and SPOTD threat detection technology at the U.S. Army's 2026 Joint Protection Combined Expo (JPCE) at Fort Leonard Wood, Missouri, from April 28–29, 2026. The multi-day event at Fort Leonard Wood (FLW) is headlined by the Protection Senior Leader Forum, which facilitates dialogue between senior U.S. Army leaders, subject matter experts, and decision makers regarding the Maneuver Support Center of Excellence's (MSCoE) vision

2025 was a year of tenacity, strategic transactions and building traction for RedHillTalicia® business transformed:Formation of Talicia Holdings Inc. (THI) and the U.S. co-commercialization partnership with Cumberland Pharmaceuticals ("Cumberland") (NASDAQ:CPIX), including Cumberland's $4 million investment for a 30% equity interest in THI planned to drive Talicia growth, and potentially additional revenue generating products. Cumberland and Apotex1, Canadian-based global health company, have since announced their planned strategic transaction to integrate Cumberland's U.S branded business into ApotexAdded eight million lives with coverage by Humana®'s Part D Plan and published new data supp

Nominees Keith Mestrich and Donald Felix Collectively Bring Backgrounds that Directly Align with Carver's Needs, Including Experience Transforming Financial Institutions and Driving Profitability and Growth Refreshment Delivers on Previously Announced Board Modernization Commitment and is a Critically Important Part of Positioning Carver for Sustainable Profitability and Growth Management and the Board Continue to Take Decisive Actions to Improve Performance and Enhance Value for All Stockholders Vote on the WHITE Proxy Card TODAY to Elect Carver's Two Highly Qualified Candidates – Keith Mestrich and Donald Felix – to the Board  NEW YORK, April 27, 2026 /PRNewswire/ -- Carver Bancorp, Inc. (

KUALA LUMPUR, Malaysia, April 27, 2026 /PRNewswire/ -- Agroz Inc. (NASDAQ:AGRZ) ("Agroz," the "Company," "we," "us," or "our"), an innovative, fully vertically integrated agricultural technology company specializing in AI-powered Controlled Environment Agriculture ("CEA") vertical farms, today announced that its wholly owned Malaysian subsidiary, Agroz Group Sdn. Bhd., has been officially granted Malaysia Digital (MD) Status by the Government of Malaysia through the Malaysia Digital Economy Corporation ("MDEC"). The approval, granted on March 30, 2026, recognizes Agroz Group's r

Guidelines include the next-generation targeted therapy as a systemic option for patients with ROS1-positive non-small cell lung cancer with brain metastasesNEW YORK, April 27, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE:NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that taletrectinib (IBTROZI®) has been added to the latest National Comprehensive Cancer Network® Clinical Practice Guidelines (NCCN Guidelines®) in Oncology for Central Nervous System (CNS) cancers, updated on April 24, 2026. Specifically, the NCCN Guidelines® for CNS Cancers now recommend taletrectinib (IBTROZI) as a systemic therapy option for ROS1-po

Enterprise and mid-market launch expands high-value AI video SaaS capabilities and strengthens recurring revenue opportunities.WOODCLIFF LAKE, N.J., April 27, 2026 /PRNewswire/ -- Powerfleet (NASDAQ:AIOT), a global leader in the artificial intelligence of things (AIoT) SaaS mobile asset industry, announced today the launch of Vision 360 Plus, an AI-powered video multi-camera 360° coverage solution designed to enhance operational visibility and driver safety. In partnership with TELUS, a global communications technology leader serving more than 20 million customer connections, Po

LOS ANGELES, April 27, 2026 /PRNewswire/ -- Pixelworks, Inc. (NASDAQ:PXLW) ("Pixelworks" or the "Company"), a provider of innovative cinematic and enhanced visualization solutions, today announced Vice President of Technology, Yue ("Robin") Ma, will deliver a featured presentation at the World Dialogue on Art and Technology Conference to be held April 25-29, 2026 at Shanghai University in Beijing.Ma is one of eight distinguished keynote speakers invited to present at the conference. Her speech entitled "From Cinematic High Frame Rate to Immersive Cinema " will discuss how Pixelworks' TrueCut Motion technology bridges cinematic tradition and experiential features by modeling human visual perc